Abstract Statins have both cholesterol lowering and antiinflammatory activities, whether mechanisms underlying their activities are independent remains unclear. The ATPgated P2X 4 receptor is a pro-inflammatory mediator. Here, we investigate the action of fluvastatin and other cholesterol depleting agents on native and recombinant human P2X 4 receptor. Fluvastatin and mβCD suppressed P2X 4 -dependent calcium influx in THP-1 monocytes, without affecting P2Y receptor responses. mβCD or filipin III suppressed the current density of recombinant human P2X 4 receptors. Human P2X 2 was insensitive to cholesterol depletion. Cholesterol depletion had no effect on intrinsic P2X 4 receptor properties as judged by ATP concentration-response relationship, receptor rundown or current decay during agonist occupancy. These data suggest fluvastatin suppresses P2X 4 activity in monocytes through cholesterol depletion and not by modulating intrinsic channel properties.
Introduction
Statins are the most effective treatment for artherosclerosis and lowering cardiovascular risk [1] . Statins reduce cellular cholesterol through the inhibition of HMG-CoA reductase [1] , though a second anti-inflammatory action is thought to contribute to their effectiveness as anti-atherosclerosis agents. Mechanisms of anti-inflammatory action by statins remains poorly described [2, 3] . Monocytes are major participants in the progression of atherosclerosis [4] . Monocyte recruitment and retention at sites of lesion contribute to plague development by direct secretion of pro-inflammatory molecules and monocyte maturation into macrophage and dendritic cells.
Signalling via extracellular ATP is important in the induction and resolution of inflammation. P2X receptors are a family of ATP-activated calcium channel, of which seven human receptor subunits (P2X 1-7 ) have been cloned and characterised [5] . P2X 4 is highly expressed in peripheral myeloid cells [6] [7] [8] . P2X 4 expression is up-regulated in microglia following nerve damage [9, 10] . More recently, activation of P2X 4 was demonstrated to mediate PGE2 release in macrophage [10] . In light of the pro-inflammatory action of P2X 4 , this study sought to investigate whether P2X 4 is a target for fluvastatin and other cholesterol-depleting agents.
Materials and methods

Cell culture and transfection
Human THP-1 cells were cultured in RPMI medium containing 10% foetal calf serum. HEK293 cells were cultured in DMEM medium with 10% foetal calf serum at 37°C with 5% CO 2 in a humidified incubator. For electrophysiology, cells were transfected with 1 μg plasmid-encoded human P2X 4 with a C-terminal glu-glu tag or human P2X 2 (both kind gifts from Prof. R. Alan North FRS, University of Manchester). Cells were co-transfected with 0.1 μg plasmid expressing GFP alone to allow identification of transfected cells.
Intracellular calcium measurements
Cells were pre-incubated with fura-2 AM for 1 h at 37°C followed by a 0.5-h wash at room temperature. Human THP-1cells were centrifuged in the plate at 2×10 5 cells/ well. Measurements were made at room temperature on a 96-well plate reader (FlexStation, Molecular Devices). The change (Δ) in intracellular calcium (Ca i 2+ ) concentration is indicated as the ratio of fura-2 emission intensities for 340-and 380-nm excitation (F ratio). Wells within columns of the 96-well plate were loaded alternately for test and control conditions. The recording solution contained (millimolars): 130 NaCl, 5 KCl, 8 D-glucose, 10 HEPES and 1.2 MgCl2, titrated to pH 7.4 with NaOH. Ca 2+ -free extracellular solution (0 Ca 2+ ) was prepared by excluding CaCl 2 . Cells were pretreated with the reagents for 0.5 h during the washing period of the fura-2 before Ca 2+ measurements at room temperature.
Electrophysiology
Whole-cell or perforated patch recordings were made 48 following plasmid transfection. HEK293 cells were seeded onto glass covers and allowed to adhere for at least 1 h prior to recording. The extracellular solution contained (millimolars): 145 NaCl, 2 KCl, 2 CaCl 2 , 1 MgCl 2 , 13 D-glucose and 10 HEPES, pH 7.3. The intracellular pipette solution contained (millimolars): 145 NaCl, 10 EGTA and 10 HEPES, pH 7.3. The pipette solution was supplemented with 120 μg/mL amphotericin for perforated patch recordings; perforation typically occurred 5 mins after gigaseal formation. Pipettes had resistance of 3-5 MΩ. ATP was applied using an RSC 160 rapid solution changer (Biological Science Instruments, Intracell). ATP was applied for 2 s at 2-min intervals and cells were clamped at −60 mV. HEK293 cell treatment with cholesterol depleting agents was at 37°C.
Quantitative mRNA analysis
Total RNA was extracted from control and fluvastatintreated cells using TriReagent (Sigma). First-strand cDNA was synthesised using Maxima Reverse Transcriptase (Fermentas) and Oligo(dT) 18 priming. cDNA was amplified using sense and anti-sense oligonucleotide pairs selective for human P2X 4 and GAPDH using an ABI Biosystems PCR Instrument. P2X 4 mRNA abundance was expressed relative to GAPDH housekeeping gene.
Drugs and treatments
Fluvastatin sodium salt (Tocris) stock solutions were prepared to 10 mM in DMSO. For chronic treatment of monocytes, THP-1 cultures (<1×10 6 cells/mL) were supplemented with 10 μM fluvastatin or an equivalent volume of DMSO for 48 h prior to experimentation. For shorter treatments, 10 μM fluvastatin was applied 1 h prior to experimentation. Methyl-β-cyclodextrin (Sigma) was prepared in water and applied at 10 mM 1 h prior to experimentation.
Statistical analysis
Numerical data are expressed as mean±S.E. Statistical significance was tested by Student's t test and analysis of variance.
Results and discussion
Application of ATP (100 μM) to fura-2 loaded THP-1 cells robustly increased [Ca 2+ ] i (Fig. 1a ). Intracellular calcium rapidly peaked then decayed to a sustained elevated phase (Fig. 1a) . Pre-incubation with the phospholipase C inhibitor U-73122 (10 μM, 30 min) abolished the rapid peak in ATPevoked in [Ca 2+ ] i though a residual sustained calcium rise persisted (Fig. 1a) . The U-73122-resistant calcium rise was not inhibited by the selective P2X 7 antagonist AZ11645373 (1 μM, 30 min) (Fig. 1c) . Moreover 100 μM ATP is subthreshold for human P2X 7 receptor activation. The peak residual calcium component was potentiated ∼2.5-fold by ivermectin (10 μM, 30 min) (Fig. 1a) , a positive allosteric modulator of P2X 4 [11, 12] . These data strongly suggest that P2X 4 mediates the U-73122-resistant ATP-evoked calcium influx in THP-1 monocytes. P2X 1 , P2X 4 and P2X 7 mRNA transcripts have been detected in THP-1 monocytes though it is most unlikely that P2X 1 would mediate a sustained calcium influx due to its rapid desensitisation. Functional P2X 1 has been detected electrophysiologically in other inflammatory cell types [8, 13] . Pre-incubating monocytes with the cholesterol depleting agent mβCD suppressed the magnitude of P2X 4 -dependent calcium influx threefold (Fig. 1b) . The suppressed P2X 4 -dependent calcium entry could be potentiated ∼2.5-fold by ivermectin (Fig. 1b and  c) . α-Cyclodextran, an inactive analogue, had no effect (data not shown). mβCD did not suppress the ATP stimulated calcium rise observed in the absence of U-73122 (Fig. 1c) suggesting that P2Y receptor-dependent calcium signalling is unaffected by cholesterol depletion.
Next, we sought to determine whether clinically relevant cholesterol lowering drugs had a similar effect on P2X 4 -mediated calcium entry as acute chemical sequestration of cholesterol. THP-1 monocytes were cultured for 48 h with 10 μM fluvastatin to mimic clinical doses. As for mβCD treatment, fluvastatin treatment also had no effect on P2Y receptor-mediated calcium rises compared to vehicle controls (Fig. 2a) . However, fluvastatin treatment suppressed peak P2X 4 -dependent calcium response by 2-fold compared to their vehicle control counterparts (Fig. 2b) . Ivermectin was capable of potentiating suppressed P2X 4 -mediated calcium entry (Fig. 2b) . The cholesterol depleting action of statins through HMG-CoA reductase inhibition takes many hours to manifest. To this end, we tested the effect of acute treatments of fluvastatin to rule out the possibility that fluvastatin inhibits P2X 4 -dependent Ca 2+ entry via a different mechanism. Unlike 48-h treatment, 1-h treatment with 10 μM fluvastatin had no significant effect on P2X 4 -dependent Ca 2+ entry (Fig. 2c) (N04; p<0.05) . Moreover, application of mβCD to cells treated with fluvastatin for 48 h showed no significant difference in P2X 4 -dependent Ca 2+ entry compared to cells treated with fluvastatin alone (Fig. 2d) . These data indicate that fluvastatin and mβCD suppress P2X 4 receptor activity by the same mechanism. Furthermore, no significant difference was observed for the abundance of P2X 4 mRNA in control monocytes or monocytes treated with fluvastatin for 48 h (Fig. 2e) , suggesting fluvastatin does not reduce P2X 4 activity through a transcriptional influence. These data suggest P2X 4 activity is suppressed following depletion of cellular cholesterol.
To investigate the mechanism further, we explored the effects of cholesterol depletion on human P2X 4 heterologously expressed in HEK293T cells [12] . ATP (100 μM) evoked robust inward currents that moderately desensitised during agonist application (Fig. 3a) . The mean whole-cell current density was 82±8 pA/pF (N010 cells). To examine the influence of membrane cholesterol on human P2X 4 activity, we employed mβCD and filipin III, two chemically unrelated cholesterol sequestering agents. Treatment of HEK293T cells with 10 mM mβCD for 1 h significantly reduced P2X 4 current density compared to untreated cells (18±4 pA/pF; N010, p<0.01 vs control) (Fig. 3a) . The effect was not mimicked by 10 mM mαCD (95±10pA/pF; N08, p>0.05 vs control) (Fig. 3b) . Treatment with 10 μM filipin III for 30 min also significantly reduced P2X 4 current density (30±5 pA/pF; N010, p<0.01 vs control) (Fig. 3b) . Previous studies have revealed some selectivity of cholesterol depletion on P2X receptor function. As for THP-1 monocytes, ivermectin was able to potentiate P2X4 suppressed by mβCD (35±8 pA/pF; Fig. 3 Effect of cholesteroldepleting agents on human P2X 4 and P2X 2 receptors in HEK293T cells. a Representative traces showing effect of mβCD treatment of P2X 2 and P2X 4 currents in HEK293 cells, and the effect of fluvastatin (10 μM, 48 h) on P2X 4 currents. b Pooled averages demonstrated reduction in P2X 4 current density following cholesterol depletion by methyl-β-cyclodextrin or filipin III, but not by αCD. Ivermectin (IVM; 10 μM, 30 min). Fluvastatin (10 μM, 48 h). N08; *p<0.01 vs control, #p<0.01 vs mβCD treatment. c P2X 2 currents are unaffected cholesterol depletion, N08. All currents evoked by 100 μM ATP N05, p<0.01 vs control) (Fig. 3b) . Forty-eight-hour treatment with fluvastatin (10 μM) significantly reduced P2X 4 peak current density (Fig. 3a and b) .
Cholesterol depletion suppresses P2X 1 function when expressed in HEK293 cells [14, 15] but not P2X 2 or P2X 3 [15] . Native P2X 3 currents are also unaffected by cholesterol depletion [16] . Consistent with previous studies [15] , ATPevoked currents were unaffected by cholesterol depletion in HEK293T cells expressing human P2X 2 receptor (Fig. 3a) . ATP (100 μM) evoked an average current density of 620± 30 pA/pF (N09 cells) in control cells which was unaffected by mβCD (661±30pA/pF, N08cells) or filipin III (640± 30pA/pF) (Fig. 3c ). Our observations of the effect of cholesterol depletion on native and transiently expressed P2X 4 receptor are in contrast to those of Allsopp et al. (2010) who employed stable P2X 4 HEK293 cells. A main difference between this study and that of Allsopp et al. (2010) is that electrophysiological recordings have been made using the perforated patch configuration. Statins may therefore impinge on intracellular factors that regulate P2X4R function and/or trafficking which are dialysed out during whole-cell recordings. Indeed, patch perforation minimises the extensive rundown of P2X4R activity observed in whole-cell recordings [12] . The data presented here suggests that the effect of cholesterol depletion is consistent between native and recombinant human P2X 4 receptors.
P2X receptor current density is governed by multiple factors including responsiveness to ATP, receptor desensitisation and receptor number. ATP concentration-response curves were not significantly different between control and cholesterol depleted cells (Fig. 4a) . The EC 50 value for control cells was 2.5±1.2 μM (N010 cells), comparable to previous studies [17] , and 2.1±2.0 μM and 2.2±1.4 μM for mβCD and filipin III-treated cells, respectively (both N010 cells; p>0.05 vs control). Responses were recorded using the perforated patch configuration to minimise receptor rundown [12] . The effects of cholesterol depletion on two modes of receptor desensitisation were also tested. The human P2X 4 receptor runs down with repeated agonist application [12] . In control cells, repeated application of 100 μM ATP at 2 min intervals was marked with an exponential decay in peak whole-cell current (τ01.19±0.05; N08). The rate of rundown was unaffected by cholesterol depletion; τ01.19±0.08 and 1.10±0.08 (N08 cells each, p>0.05 vs control) for mβCD and filipin IIItreated cells, respectively (Fig. 4b) . Human P2X 4 currents decayed by 51.5±1.5% (N08 cells) during application of 100 μM ATP (Fig. 4c) . Again, cholesterol depletion had no effect on the magnitude of current decay; 46.9±4.3% and 50.2±2.5% (N08 cells each; p>0.05 vs control) for mβCD and filipin III-treated cells, respectively ( Fig. 4c and d) . These data support the notion that P2X 4 current density and receptor desensitisation during agonist occupancy are independent [12] . In summary, this study suggests that fluvastatin inhibits P2X 4 through its cholesterol depleting activity, as fluvastatin, mβCD and filipin III produce the same outcome. The mechanism underlying suppression of P2X4 does not involve modulation of intrinsic channel properties and is therefore likely to be a consequence of interfering in mechanisms controlling receptor trafficking or regulation by signal transduction or protein-protein interaction. Disruption of lipid raft-dependent signalling is a possible mechanism of action of fluvastatin. The existence of P2X 4 in lipid rafts has been demonstrated in epithelia [18] and HEK293 cells [15] . Indeed, fluvastatin inhibits raft-dependent signalling in monocytes [19] .
